Maria Jesús Vidal
Research group
- Translational genomics and targeted therapies in solid tumours Accredited researcher (R3A)
Featured publications
-
Sentinel node after NeoAdjuvancy in node-positive breast cancer. SANA multicentric study
Authors:Reference: European Journal Of Cancer 2020. -
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
Authors:Reference: Jama Oncology 2020. -
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Authors:Reference: Breast Cancer Research 2020. -
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Authors:Reference: Cancer Treatment Reviews 2020. -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Authors:Reference: Nature Communications 2020. -
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Authors:Reference: Journal Of The National Cancer Institute 2020. -
PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer
Authors:Reference: Annals Of Oncology 2019.
Featured Projects
-
HER2-enriched molecular subtype as a predictor of response to dual HER2 blockade.
Principal investigator: Aleix PratFunder: Beca Susan Komen (Sede o evento)Duration: 01/01/2014 - 01/01/2016 -
Predictores de Respuesta a la Quimioterapia en Cáncer de Mama Triple-Negativo con un Perfil Molecular Basal-like.
Principal investigator: Aleix PratFunder: Beca Sandra Ibarra (Sede o evento)Duration: 01/01/2013 - 01/01/2013 -
Molecular Quantification of Estrogen Receptor Partners for Endocrine Response Prediction.
Funder: Universidad de Oslo (Sede o evento)Duration: 01/01/2012 - 01/01/2016